

## DAFTAR PUSTAKA

1. Weaver AL, Lincoln N, Gitlin N. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs. *Arch Intern Med*. 2002;162(19):2248–9.
2. Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI, Blaser MJ. *Helicobacter pylori* infection and the risk for duodenal and gastric ulceration. *Ann Intern Med*. 1994;120(12):977–81.
3. Schöttker B, Adamu MA, Weck MN, Brenner H. *Helicobacter pylori* Infection Is Strongly Associated With Gastric and Duodenal Ulcers in a Large Prospective Study. *Clin Gastroenterol Hepatol* [Internet]. 2012;10(5):487-493.e1. Available from: <http://dx.doi.org/10.1016/j.cgh.2011.12.036>
4. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D BF. Meta-analysis: can *Helicobacter pylori* eradication treatment reduce the risk for gastric cancer? *Ann Intern Med*. 2009;151:121–8.
5. Dore MP, Pes GM, Bassotti G, Usai-Satta P. Dyspepsia: When and how to test for *helicobacter pylori* infection. *Gastroenterol Res Pract*. 2016;2016.
6. Vandenas Y HB. *Helicobacter pylori* infection. *Acta Pediatr Tw*. 1999;(40):212–24.
7. Peek RM BM. Pathophysiology of *Helicobacter pylori* infection in children: a consensus statement. *Am J Med*. 1997;(102):200–7.
8. Hegar B, Magdalena FA. Infeksi *Helicobacter pylori* pada murid sekolah dasar di Jakarta. *Maj Kedokt Indon*. (48):209–12.
9. C. T. Wawancara atau Komunikasi Pribadi dengan Dokter Spesialis Penyakit Dalam. 2014;
10. Utia, K., Syam, A.F., Simadibrata, M, Setiati, S. dan Manan, C. Clinical Evaluation of Dyspepsia with The Story of *Helicobacter Pylori* Eradication Therapy in Cipto Mangunkusumo Hospital Jakarta. *J Gastroenterol Dig Endosmegracopy*. 2010;86–93.
11. Malfertheiner P, Megraud F, O’Morain CO, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of *helicobacter pylori* infection - The maastricht III consensus report. *Chinese J Gastroenterol*. 2007;12(3):159.
12. Dammann HG, Fölsch UR, Hahn EG, Von Kleist DH, Klör HU, Kirchner T, et al. Eradication of *H. pylori* with Pantoprazole, Clarithromycin, and Metronidazole in Duodenal Ulcer Patients: A Head-to-Head Comparison

- Between Two Regimens of Different Duration. *Helicobacter*. 2000;5(1):41–51.
13. Gerhard M, Rad R, Prinz G NM. Pathogenesis of *Helicobacter pylori* infection. *Helicobacter*. 2002;7(sup):17–23.
  14. Glupczynski Y, Mégraud F, Lopez-Brea M, Andersen L. European multicentre survey of in vitro antimicrobial resistance in *Helicobacter pylori*. *Eur J Clin Microbiol Infect Dis*. 2001;20(11):820–3.
  15. Mégraud F. Surveillance nationale des maladies infectieuses 1998-2000. St Maurice, Fr Inst Veill Sanit. 2003;327–9.
  16. Parsons HK, Carter MJ, Sanders DS, Winstanley T, Lobo AJ. *Helicobacter pylori* antimicrobial resistance in the United Kingdom: The effect of age, sex and socio-economic status. *Aliment Pharmacol Ther*. 2001;15(9):1473–8.
  17. Vakil N. *Helicobacter pylori* treatment: a practical approach. *Am J Gastroenterol*. 2006;101:497–9.
  18. Sartika RAD. Pengaruh Asam Lemak Jenuh, Tidak Jenuh dan Asam Lemak Trans terhadap Kesehatan. *Kesmas Natl Public Heal J*. 2008;2(4):154.
  19. Bergsson G, Steingrímsson Ó, Thormar H. Bactericidal effects of fatty acids and monoglycerides on *Helicobacter pylori*. *Int J Antimicrob Agents*. 2002 Oct 1;20(4):258–62.
  20. Zhang MJ, Spite M. Resolvins: Anti-Inflammatory and Proresolving Mediators Derived from Omega-3 Polyunsaturated Fatty Acids. *Annu Rev Nutr*. 2012 Aug 21;32(1):203–27.
  21. Han YM, Park JM, Jeong M, Yoo JH, Kim WH, Shin SP, et al. Dietary, non-microbial intervention to prevent *Helicobacter pylori*-associated gastric diseases. Vol. 3, *Annals of Translational Medicine*. AME Publishing Company; 2015.
  22. Turner D, S Shah P, Steinhart AH, Zlotkin S M. inflammatory bowel disease using omega-3 fatty acids (fish oil): A systemic review and meta-analyses. *Inflamm. Bowel. Dis*. 2011;(17):336–45.
  23. C Calder P. Polyunsaturated fatty acids and inflammatory processes: New twists in and old tale. *Biochimie*. 2009;(91):791–5.
  24. Meier R, Wettstein A, Drewe J, Geiser HR. Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther*. 2001;15(6):851–5.
  25. Frieri G, Pimpo MT, Palombieri A, Melideo D, Marcheggiano A, Caprilli

- R, et al. Polyunsaturated fatty acid dietary supplementation: An adjuvant approach to treatment of *Helicobacter pylori* infection. *Nutr Res.* 2000;20(7):907–16.
26. Thompson L, Cockayne A, Spiller RC. Inhibitory effect of polyunsaturated fatty acids on the growth of *Helicobacter pylori*: A possible explanation of the effect of diet on peptic ulceration. *Gut.* 1994;35(11):1557–61.
  27. M. Correia, V. Michel HO et al. “Crosstalk between *Helicobacter pylori* and gastric epithelial cells is impaired by docosahexaenoic acid,” *PLoS ONE*, vol. 8, no. 4, Article ID e60657, 2013.
  28. Correia M, Michel V, Matos AA, Carvalho P, Oliveira MJ, Ferreira RM, et al. Docosahexaenoic acid inhibits *Helicobacter pylori* growth in vitro and mice gastric mucosa colonization. *PLoS One.* 2012;7(4).
  29. Le PNT, Desbois AP. Antibacterial effect of eicosapentaenoic acid against *Bacillus cereus* and *Staphylococcus aureus*: Killing kinetics, selection for resistance, and potential cellular target. *Mar Drugs.* 2017 Nov 1;15(11).
  30. Longo, D.L., Fauci, A.S., Kasper, D.L., Hauser, J.L., Jameson, J.L. dan Loscalzo L. *Harrison’s Principles of Internal Medicine*, 18th edition. McGraw-Hill Co Inc, USA. 1:293–9.
  31. Desbois AP, Smith VJ. Antibacterial free fatty acids: Activities, mechanisms of action and biotechnological potential. *Appl Microbiol Biotechnol.* 2010;85(6):1629–42.
  32. Saito H, Tomioka H YT. Growth of group IV mycobacteria on medium containing various saturated and unsaturated fatty acids. *Antimicrob Agents Chemother* 26:164–169. 1984;
  33. Kabara JJ, Vrable R LKJM. Antimicrobial lipids: natural and synthetic fatty acids and monoglycerides. *Lipids* 12:753–759. 1977;
  34. Your Digestive System & How it Works [Internet]. National Institute of Diabetes and Digestive and Kidney Disease. Available from: <https://www.niddk.nih.gov/health-information/digestive-diseases/digestive-system-how-it-works>
  35. Drake RL, Vogt W, Adam W.M. Mitchell. *Gray’s Basic Anatomy International Ed.* Elsevier; 1389.
  36. Allen WE. *diFiore’s Atlas of Histology with Functional Correlations* (11th Edition). *J Anat.* 2008 Sep;213(3):357–8.
  37. Goodwin CS, McCulloch RK, Armstrong JA, Wee SH. Unusual cellular fatty acids and distinctive ultrastructure in a new spiral bacterium (*Campylobacter pyloridis*) from the human gastric mucosa. *J Med*

- Microbiol. 1985;19(2):257–67.
38. Jones DM, Curry A, Fox AJ. An ultrastructural study of the gastric campylobacter-like organism “Campylobacter pyloridis.” *J Gen Microbiol.* 1985;131(9):2335–41.
  39. Krzyzek P, Gościński G. Morphology of *Helicobacter pylori* as a result of peptidoglycan and cytoskeleton rearrangements. Vol. 13, *Przegląd Gastroenterologiczny.* 2018.
  40. Kim N. Synopsis of *H. pylori*-associated diseases. *Helicobacter pylori.* 2016. 175–185 p.
  41. Poursina F, Faghri J, Moghim S, Zarkesh-Esfahani H, Nasr-Esfahani B, Fazeli H, et al. Assessment of *cagE* and *babA* mRNA expression during morphological conversion of *Helicobacter pylori* from spiral to coccoid. *Curr Microbiol.* 2013;66(4):406–13.
  42. Marshall et al. *Helicobacter pylori* [Internet]. ITIS Report. 1985. Available from: [https://www.itis.gov/servlet/SingleRpt/SingleRpt?search\\_topic=TSN&search\\_value=962224#null](https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=962224#null)
  43. Testerman TL, McGee DJ, Mobley HLT. Adherence and Colonization. In: *Helicobacter pylori.* ASM Press; 2014. p. 379–417.
  44. Appelmelk BJ, Vandenbroucke-Grauls CMJE. Lipopolysaccharide Lewis Antigens. In: *Helicobacter pylori.* ASM Press; 2014. p. 419–28.
  45. Wu JCY. Asian consensus report on functional dyspepsia: Necessary and ready? *J Gastroenterol Hepatol.* 2012;27(4):624–5.
  46. Rani AA, Fauzi A. Infeksi *Helicobacter Pylori* Dan Penyakit Gastro-duodenal. In: Sudoyo A R, Setiyohadi H, Alwi I, Kolopaking M S, Setiati A, editor. *Buku Ajar Ilmu Penyakit Dalam.* 1st ed. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI; 2006. p. 331–5.
  47. Syam AF, Abdullah M, Rani AA, Nurdjanah S, Adi P, Djumhana A, et al. Evaluation of the use of rapid urease test: Pronto dryt o detect *H pylori* in patients with dyspepsia in several cities in Indonesia. *World J Gastroenterol.* 2006;12(38):6216–8.
  48. Hidayati PS, Iswan Abbas Nusi IA, Maimunah U. Hubungan Seropositivitas *CagA H.pylori* dengan Derajat Keparahan Gastritis pada Pasien Dispepsia. 2013;
  49. Parewangi AML. Jumlah data *Helicobacter pylori* positif di Makassar. Makassar; 2011.
  50. Jumlah data *Helicobacter pylori* positif.

51. Ford AC MP. Dyspepsia. *Curr Opin Gastroenterol*. 2013;(29):662–8.
52. Futagami S, Shimpuku M, Yin Y, Shindo T, Kodaka Y, Nagoya H, et al. Pathophysiology of functional dyspepsia. *J Nippon Med Sch*. 2011;78(5).
53. Choung RS, Talley NJ. Novel mechanisms in functional dyspepsia. Vol. 12, *World Journal of Gastroenterology*. 2006.
54. Harmon RC, Peura DA. Evaluation and management of dyspepsia. Vol. 3, *Therapeutic Advances in Gastroenterology*. 2010.
55. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. World gastroenterology organisation global guideline. Vol. 20, *Journal of Gastrointestinal and Liver Diseases*. 2011.
56. Syam AF, Abdullah M, Rani AA, Nurdjanah S, Adi P, Djumhana A, et al. A comparison of 5 or 7 days of rabeprazole triple therapy for eradication of Helicobacter pylori. *Med J Indones*. 2010;19(2).
57. Ferguson JJA, Dias CB, Garg ML. Omega-3 polyunsaturated fatty acids and hyperlipidaemias. In: *Omega-3 Fatty Acids: Keys to Nutritional Health*. Springer International Publishing; 2016. p. 67–78.
58. Bethesda (MD): National Library of Medicine (US) NC for BI. Eicosapentaenoic acid [Internet]. PubChem. 2004. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Eicosapentaenoic-acid>
59. Bethesda (MD): National Library of Medicine (US) NC for BI. Docosahexaenoic acid [Internet]. PubChem. 2004. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Docosahexaenoic-acid>
60. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. *Curr Gastroenterol Rep*. 2008;10(6):528–34.
61. Mössner J. Indikationen, Nutzen und Risiken von Protonenpumpeninhibitoren. *Dtsch Arztebl Int*. 2016;113(27–28):477–83.
62. Spechler SJ. Proton Pump Inhibitors: What the Internist Needs to Know. *Med Clin North Am* [Internet]. 2019;103(1):1–14. Available from: <https://doi.org/10.1016/j.mcna.2018.08.001>
63. Yu LY, Sun LN, Zhang XH, Li YQ, Yu L, Yuan ZQY, et al. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors. *Adv Ther*. 2017;34(5):1070–86.
64. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors [Internet]. FDA Drug Safety Communication. 2011. Available from: <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication->

possible-increased-risk-fractures-hip-wrist-and-spine-use-proton-pump

65. Bethesda (MD): National Library of Medicine (US) NC for BI. Amoxicillin [Internet]. PubChem. 2004. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Amoxicillin>
66. Weber DJ, Tolkoff-Rubin NE, Rubin RH. Amoxicillin and Potassium Clavulanate: An Antibiotic Combination Mechanism of Action, Pharmacokinetics, Antimicrobial Spectrum, Clinical Efficacy and Adverse Effects. *Pharmacother J Hum Pharmacol Drug Ther.* 1984;4(3).
67. Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJC, Hicks LA, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. *Clin Infect Dis.* 2012;54(8).
68. Hendricks KA, Wright ME, Shadomy S V., Bradley JS, Morrow MG, Pavia AT, et al. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. In: *Emerging infectious diseases.* 2014.
69. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and Management of Penicillin Allergy: A Review. Vol. 321, *JAMA - Journal of the American Medical Association.* 2019.
70. FDA. Amoxil (amoxicillin capsules, tablets, chewable tablets, and powder for oral suspension). 2006;(40):4–21. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/050760s11,050761s11,050754s12,050542s25lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050760s11,050761s11,050754s12,050542s25lbl.pdf)
71. Frascini F, Scaglione F, Demartini G. Clarithromycin Clinical Pharmacokinetics. 1993;25(3):189–204.
72. Bethesda (MD): National Library of Medicine (US) NC for BI. Clarithromycin [Internet]. PubChem. 2004. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Clarithromycin>
73. Kumaresan R. Current Pharmaceutical & Clinical EFFECTS OF CLARITHROMYCIN ON CARDIOVASCULAR SYSTEM – A REVIEW. 2019;(February).
74. Class A, Spectrum MA, Effects A. Clarithromycin.
75. Clarithromycin D, No Y, No B. BIAXIN ® Filmtab ® ( clarithromycin tablets , USP ) BIAXIN ® XL Filmtab ® ( clarithromycin extended-release tablets ) BIAXIN ® Granules ( clarithromycin for oral suspension , USP ). (10).
76. Varghese N, Joy PP. Naveena Varghese. 2016;(January 2014).
77. Figura N, Marcolongo R, Cavallo G, Santucci A, Collodel G, Spreafico A,

- et al. Polysorbate 80 and *Helicobacter pylori*: A microbiological and ultrastructural study. *BMC Microbiol.* 2012;12.
78. Noto JM, Peek RM. *Helicobacter* Species. *methods Mol Biol.* 2012;921(22):41–50.
  79. Thirunavukkarasu P, Asha S, Kumarreddy R, Ramanathan T, Sudhakar N. Survey, isolation, biochemical characterization, and identification of *Helicobacter pylori* from gastric patient biopsy. *Asian J Pharm Clin Res.* 2017;10(6):411–6.
  80. Wales PH SM. *UK Standards of Microbiology Investigations.* 2015;1–14.
  81. Piccolomini R, Di Bonaventura G, Catamo G, Carbone F, Neri M. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of *Helicobacter pylori* strains to 20 antimicrobial agents. *J Clin Microbiol.* 1997 Jul;35(7):1842–6.
  82. Balouiri M, Sadiki M, Ibsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. *J Pharm Anal [Internet].* 2016;6(2):71–9. Available from: <http://dx.doi.org/10.1016/j.jpha.2015.11.005>
  83. Health NI of. Omega-3 Fatty Acids [Internet]. [cited 2021 Jan 21]. Available from: <https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/>
  84. Microchem Laboratory. Zone of Inhibition test for antimicrobial activity. 2015;
  85. Shin SY, Bajpai VK, Kim HR, Kang SC. Antibacterial activity of bioconverted eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) against foodborne pathogenic bacteria. *Int J Food Microbiol.* 2007;113(2):233–6.
  86. Chanda W, Joseph TP, Guo XF, Wang WD, Liu M, Vuai MS, et al. Effectiveness of omega-3 polyunsaturated fatty acids against microbial pathogens. *J Zhejiang Univ Sci B.* 2018;19(4):253–62.
  87. Ribeiro-Vidal H, Sánchez MC, Alonso-Español A, Figuero E, Ciudad MJ, Collado L, et al. Antimicrobial activity of epa and dha against oral pathogenic bacteria using an in vitro multi-species subgingival biofilm model. *Nutrients.* 2020;12(9):1–17.